Arrowhead Pharmaceuticals (ARWR) Stock Analysis & AI Equity Report
Arrowhead Pharmaceuticals (ARWR) overview
Arrowhead Pharmaceuticals (ARWR) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 451m and operating profit of USD -707m; the year-end share price was 65.45 USD and market capitalisation was USD 9,247m. Arrowhead Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arrowhead Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that silence genes associated with disease using RNA interference and a portfolio of RNA chemistries and delivery methods. Its marketed product, REDEMPLO, is used with diet to reduce triglycerides in adults with familial chylomicronemia syndrome. The company also develops drug candidates at various clinical stages and licenses or collaborates on programs it does not plan to commercialize independently.
Generate the Arrowhead Pharmaceuticals report
Arrowhead Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Arrowhead Pharmaceuticals and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Arrowhead Pharmaceuticals
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.